Vertex Forecasts 8–9% 2025 Revenue Growth as Renal Pipeline Surges and ALYFTREK, JOURNAVX Launch Drive Diversification

Strong Performance and Strategic Growth

Vertex Pharmaceuticals (VRTX) delivered impressive results in the third quarter of 2025, with $3.08 billion in revenue, reflecting double-digit growth compared to the same period in 2024. CEO Reshma Kewalramani emphasized that the company is not only leading in cystic fibrosis (CF) but also diversifying its revenue streams through products like CASGEVY and JOURNAVX, which are gaining traction globally.

Kewalramani highlighted several pipeline advancements, including the expansion of ALYFTREK for younger CF patients, pivotal data for TRIKAFTA in 1- to 2-year-olds, and progress on VX-828 and VX-522. She also noted the full enrollment of the RAINIER Phase 3 trial for povetacicept (pove) in IgAN, an expedited BLA submission, and preparations for multiple kidney indications.

Duncan J. McKechnie, Chief Commercial Officer, reported strong double-digit growth in the CF franchise, with rapid uptake of ALYFTREK among newly eligible and transition patients. He mentioned that nearly 300 patients have been referred by their physicians to an ATC to initiate the [CASGEVY] treatment process, with 39 patients having received infusions.

McKechnie also discussed JOURNAVX’s success, noting that more than 300,000 prescriptions were filled as of mid-October. He added that preparations are underway to add 150 additional representatives in the first quarter of 2026.

CFO Charles Wagner stated that total revenue increased 11% year-over-year to $3.08 billion, with U.S. revenue growth of 15% driven by ongoing patient demand and favorable net pricing. He also mentioned that $17 million of CASGEVY revenue and $20 million from JOURNAVX contributed to the regional growth rates.

Outlook and Financial Results

Wagner announced that Vertex now expects 2025 total revenue to be in a range of $11.9 billion to $12 billion, up from prior guidance of $11.85 billion to $12 billion. This represents growth of approximately 8% to 9% for the full year at current exchange rates.

He indicated that full-year operating expense guidance is now $5 billion to $5.1 billion, up from prior guidance, due to the acceleration in pove development programs and increased investment in commercial and marketing activities to support the launch of JOURNAVX. Wagner also lowered the expected full-year 2025 non-GAAP effective tax rate guidance from a range of 20.5% to 21.5% to a revised range of 17% to 18%.

Wagner reported that combined non-GAAP R&D acquired IP R&D and SG&A expenses were $1.28 billion in Q3 2025, compared to $1.08 billion in the same period in 2024. Non-GAAP earnings per share were $4.80, an increase of 10% compared to $4.38 in Q3 2024. Vertex ended Q3 with $12 billion in cash and investments after repurchasing more than 2.7 million shares for approximately $1.1 billion.

Q&A Highlights

Geoffrey Meacham from Citigroup asked about ALYFTREK’s transition trends and monitoring requirements, as well as differentiation for pove in a competitive landscape. McKechnie responded that the vast majority of newly eligible patients in the U.S. have started on ALYFTREK, generating close to $0.5 billion in revenue since its launch.

Salveen Richter from Goldman Sachs inquired about pove’s read-through to eGFR benefit and JOURNAVX’s third PBM coverage. Kewalramani explained the importance of proteinuria reduction for eGFR stabilization, while McKechnie cited ongoing progress with the third PBM and prescription growth.

Jessica Fye from JPMorgan sought capital allocation priorities. Wagner stated that the top priority is reinvesting in the business to drive innovation and growth, with a secondary focus on share buybacks.

Tazeen Ahmad from BofA asked about the FDA’s rationale for pove’s early filing and breakthrough designation. Kewalramani noted that the company had discussions with the agency and reviewed all data to date, which led to the breakthrough designation.

William Pickering from Bernstein requested a comparison of pMN market size and competitive context. Kewalramani stated that Vertex is the only company with APRIL/BAFF in pivotal development for membranous.

Sentiment Analysis and Risks

Analysts maintained a neutral to slightly positive tone, focusing on commercial execution, pipeline milestones, and payer coverage, with some probing on competitive differentiation and BD strategy. Management remained confident and upbeat, frequently expressing high expectations for pipeline programs and commercial launches.

Compared to last quarter, management’s tone remained confident, while analysts were similarly constructive but pressed for additional detail on payer access and new product uptake.

Quarter-over-Quarter Comparison

Revenue guidance moved slightly higher, now $11.9–$12.0 billion versus the prior $11.85–$12.0 billion. Notable increases in operating expense guidance reflect accelerated pipeline and commercial investments.

Progression in pipeline includes full enrollment of pivotal pove study, strong prescription growth for JOURNAVX, and expanded ALYFTREK launches in Europe. Analysts’ questions this quarter skewed more toward product differentiation and payer coverage than pipeline uncertainties, compared to previous quarters' focus on pipeline breadth and early-stage assets.

Final Takeaway

Vertex management emphasized strong double-digit revenue growth in Q3 2025, ongoing commercial momentum for ALYFTREK, CASGEVY, and JOURNAVX, and significant advancement of its renal pipeline. With revenue guidance now at $11.9–$12.0 billion and preparations for multiple product launches underway, the company aims to sustain growth through continued investment in R&D and commercial expansion, while managing near-term risks and capital allocation priorities.